Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ: ACLX )

86.40 +0.97 (+1.14%)
Streaming Delayed Price Updated: 1:58 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Analyst Ratings for Arcellx
Via Benzinga
Why Arcellx (ACLX) Stock Is Nosediving
Arcellx Inc (NASDAQ: ACLX) shares are trading lower by 8.50% to $32.76 Tuesday morning after the FDA on Monday put a clinical hold on the company's multiple myeloma phase 2 trial. 
Via Benzinga
The Latest Analyst Ratings for Arcellx
Via Benzinga
Where Arcellx Stands With Analysts
Via Benzinga
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T. 
Via InvestorPlace
Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential
The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 Clinical Program. 
Via Benzinga
Exposures Product Safety
FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study
The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2  
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex. 
Via Investor's Business Daily
What 5 Analyst Ratings Have To Say About Arcellx
Via Benzinga
Where Arcellx Stands With Analysts
Via Benzinga
Why Is Arcellx (ACLX) Stock Up 25% Today?
ACLX stock is usually under the radar, but today it's in the spotlight as Arcellx reveals a team-up with a well-known biotech business. 
Via InvestorPlace
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740. 
Via Benzinga
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for  
Via Benzinga
Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning! 
Via InvestorPlace
Alibaba, Arcellx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023
Via Benzinga
20 Favorite Biotech & Medical Stocks For 2023
The way these stocks are setting up, many of them look great and will be at the forefront this coming year. 
Via Talk Markets
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
Dow Tumbles 100 Points; Silver Rises Over 2%
U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday 
Via Benzinga
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate. 
Via Benzinga
US Stocks Turn Higher; Nasdaq Rises 40 Points
U.S. stocks traded slightly midway through trading with the Nasdaq gaining over 40 points on Friday 
Via Benzinga
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
The company inked a deal worth $325 million and up to $3.9 billion in milestones. 
Via Investor's Business Daily
US Stocks Edge Lower; Producer Prices Increase Higher Than Expected
U.S. stocks traded slightly lower this morning following the release of PPI data 
Via Benzinga
Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.